The cost-effectiveness of neonatal versus prenatal screening for congenital toxoplasmosis.

Christine BinquetCatherine LejeuneValérie SerorFrançois PeyronAnne-Claire BertauxOlivier ScemamaCatherine QuantinSophie BéjeanEileen StillwaggonMartine Wallon

Published in: PloS one (2019)

Prenatal screening is cost-effective as compared to neonatal screening in moderate prevalence areas with predominant Type II strains. In addition, prenatal screening, by providing closer follow-up of women at risk increases the number of occasions for education avoiding toxoplasmosis.

Keyphrases

pregnant women
healthcare
escherichia coli
risk factors
type diabetes
high intensity